Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD – Get Free Report) saw a significant decrease in short interest in May. As of May 29th, there was short interest totaling 57,741 shares, a decrease of 57.1% from the May 14th total of 134,469 shares. Based on an average trading volume of 40,907 shares, the short-interest ratio is presently 1.4 days. Approximately 0.5% of the company’s shares are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Analysis on Hong Kong Pharma Digital Technology
Hong Kong Pharma Digital Technology Stock Performance
Hong Kong Pharma Digital Technology (NASDAQ:HKPD – Get Free Report) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $3.57 million for the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD – Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the SEC.
Hong Kong Pharma Digital Technology Company Profile
Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.
Featured Stories
- Five stocks we like better than Hong Kong Pharma Digital Technology
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Receive News & Ratings for Hong Kong Pharma Digital Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hong Kong Pharma Digital Technology and related companies with MarketBeat.com's FREE daily email newsletter.
